Research graph
References from Combined amivantamab, lazertinib, and bevacizumab in patients with EGFR-mutant advanced non-small-cell lung cancer with acquired resistance to a third-generation EGFR tyrosine-kinase inhibitor (ETOP 18-21 AMAZE-lung): a prospective, international, multicentre, single-arm, phase 2 trial. Local targets link to admitted publications; unresolved targets remain external evidence.
Updated treatment recommendations for systemic treatment: from the ESMO oncogene-addicted metastatic NSCLC living guideline
10.1016/j.annonc.2025.06.007 · 2025 · External reference
Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: mechanisms and therapeutic strategies
10.1016/j.ctrv.2018.02.006 · 2018 · External reference
Amivantamab (JNJ-61186372), an Fc enhanced EGFR/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte/macrophage trogocytosis
10.1158/1535-7163.mct-20-0071 · 2020 · External reference
Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC
10.1056/nejmoa2403614 · 2024 · External reference
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
10.1016/j.annonc.2023.10.117 · 2024 · External reference
Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
2023 · External reference
Clonal evolution and heterogeneity of osimertinib acquired resistance mechanisms in EGFR mutant lung cancer
2020 · External reference
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance
10.1158/1078-0432.ccr-08-2904 · 2009 · External reference
Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation
10.1097/jto.0000000000000170 · 2014 · External reference
Risk factors for venous thromboembolism (VTE) among patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) receiving amivantamab plus lazertinib versus either agent alone
2023 · External reference
JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC)
2019 · External reference
Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: analysis from the CHRYSALIS study
10.1016/j.annonc.2021.08.1797 · 2021 · External reference
Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial
10.1038/s41591-023-02554-7 · 2023 · External reference
Phase III, randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR- or ALK-mutated non-small-cell lung cancer (ATTLAS, KCSG-LU19-04)
10.1200/jco.23.01891 · 2024 · External reference
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
10.1016/s2213-2600(19)30084-0 · 2019 · External reference
Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial
10.1038/s41591-025-03658-y · 2025 · External reference
Nivolumab plus chemotherapy in epidermal growth factor receptor-mutated metastatic non-small-cell lung cancer after disease progression on epidermal growth factor receptor tyrosine kinase inhibitors: final results of CheckMate 722
10.1200/jco.23.01017 · 2024 · External reference
Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor-resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer
10.1200/jco.23.02747 · 2024 · External reference
Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: the phase 3 HERTHENA-Lung02 study
2025 · External reference
COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib
10.1016/j.esmoop.2025.105807 · 2025 · External reference
Ivonescimab vs placebo plus chemo, phase 3 in patients with EGFR+ NSCLC progressed with 3rd gen EGFR-TKI treatment: HARMONi
10.1016/j.jtho.2025.09.017 · 2025 · External reference
Sacituzumab tirumotecan in EGFR-TKI-resistant, EGFR-mutated advanced NSCLC
10.1056/nejmoa2512071 · 2026 · External reference
A multicenter open-label randomized phase II study of osimertinib with and without ramucirumab in tyrosine kinase inhibitor-naïve EGFR-mutant metastatic non-small cell lung cancer (RAMOSE trial)
10.1200/jco.24.00533 · 2025 · External reference
10.1016/s1470-2045(22)00382-5
10.1016/s1470-2045(22)00382-5 · 2022 · External reference
Preventing infusion-related reactions with intravenous amivantamab—results from SKIPPirr, a phase 2 study: a brief report
10.1016/j.jtho.2025.01.018 · 2025 · External reference
Enhanced versus standard dermatologic management with amivantamab-lazertinib in EGFR-mutated advanced NSCLC: the COCOON global randomized controlled trial
10.1016/j.jtho.2025.07.117 · 2025 · External reference
Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis
10.1001/jama.2008.656 · 2008 · External reference
Amivantamab plus lazertinib in patients with EGFR-mutant NSCLC after progression on osimertinib and platinum-based chemotherapy: results from CHRYSALIS-2 cohort A
10.1016/j.jtho.2024.12.029 · 2025 · External reference
Amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer: results from CHRYSALIS-2
10.1200/jco-24-02835 · 2026 · External reference
Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC
10.1056/nejmoa2306434 · 2023 · External reference
Overall survival with amivantamab-lazertinib in EGFR-mutated advanced NSCLC
10.1056/nejmoa2503001 · 2025 · External reference
Survival with osimertinib plus chemotherapy in EGFR-mutated advanced NSCLC
10.1056/nejmoa2510308 · 2026 · External reference
EGFR mutation status on brain metastases from non-small cell lung cancer
10.1016/j.lungcan.2016.04.004 · 2016 · External reference
Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant: a randomized clinical trial
10.1001/jama.2024.10613 · 2024 · External reference
Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: bridging biological insights and therapeutic development
10.1016/j.ctrv.2024.102824 · 2024 · External reference
Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study
10.1016/j.annonc.2025.04.003 · 2025 · External reference
Unresolved reference
2025 · External reference
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
10.1016/s1470-2045(24)00270-5 · 2024 · External reference
Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib
10.1016/j.annonc.2025.01.001 · 2025 · External reference
